Rare Disease Report

Inaugural RARE Partnering and Investor Forum Will Advise Those Looking to Invest in Orphan Drugs

JULY 12, 2017
James Radke
Do you have an orphan drug business idea?
Are you hoping to use some of your advocacy funds to directly develop drugs that will help your patients?
Are you looking to learn more about venture capitalism and drug development?
Do you want to understand how to take your brilliant idea to save rare disease patients but still pay your mortgage?
How do you learn if the investor who contacted you is legitimate?
These are just a few of the questions that will be answered this September, when Global Genes hosts the first RARE Partnering and Investor Forum, concurrent with their 6th annual RARE Patient Advocacy Summit.
The RARE Partnering and Investor Forum hopes to bring together people in the orphan drug and rare disease community to accelerate “partnering, business development, investing and licensing activities” among a multitude of parties, including scientists, universities, and non-profit foundations.
The forum will include a 1-to-1 partnering platform, a ‘shark-tank’ style pitch session and presentations, and panel discussions throughout the day (September 14th) at Hotel Irvine in Irvine, California.

Presentations/panel discussion topics will include:
  • Innovation Company Creation Models for Rare Diseases
  • Overcoming the Development Challenges of a Rare Disease Therapeutic
  • How to Ensure a Successful Commercial Launch of a Rare Disease Therapeutic
  • Alternatives to Standard Newcos: Spin-offs, Build-to-Buys, Joint Ventures and Alliances
  • Rare Disease Partnering Between Advocates, Academics, Startups and Global Pharmas
Scheduled presenters include:
  • Alison Silva, CEO & President; Critical Outcome Technologies Inc., The Orphan Group
  • Art Pappas, Managing Partner; Pappas Capital
  • Brad Margus, Co-Founder & CEO, Founder; Cerevance, A-T Children's Project
  • Bharatt Chowrira, President & Chief of Business & Strategy; PureTech Health
  • Camille Samuels, Managing Partner; Venrock
  • John Crowley, Chairman and CEO; Amicus Therapeutics
  • Jeremy Springhorn; Flagship Pioneering
  • Kush Parmar, M.D., Ph.D., Managing Partner; 5AM Ventures
  • Michael Pistone, Strategic Marketing & Business Development Leader; Cincinnati Children's Hospital Medical Center
  • Neil Kumar, PhD, CEO; BridgeBio
  • Matthew Howes, Executive Vice President, Strategy & Growth; PALIO, an inVentiv Health Company
  • Vern Norviel, Partner; Wilson Sonsini Goodrich and Rosati
  • Molly Harper, VP Commercial Development; Akcea 
For those interesting in pitching their business idea and/or entering the shark tank, registration deadline for a pitch presentation is July 15, 2017. Also, early bird pricing for the event ends on July 31, 2017.
To learn more, visit the events page on the GlobalGenes website.
Want to keep up with the upcoming rare disease events? Be sure to follow Rare Disease Report on Twitter and Facebook.

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.